OCUL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
OCUL is not a good buy right now for a Beginner with a long-term focus and $50,000-$100,000 to deploy. The stock has some meaningful upside potential from analyst enthusiasm and trial progress, but the current setup is mixed: technicals are weak, insider selling is elevated, and the company is still loss-making. Since the user is impatient and does not want to wait for a better entry, I would still avoid buying now and wait for clearer technical strength or a confirmed catalyst.
OCUL is in a weak-to-neutral technical position. MACD histogram is negative at -0.0404, showing bearish momentum, though the contraction suggests downside momentum is not accelerating. RSI_6 at 67.79 is near overbought/neutral territory, so the stock is not deeply oversold and does not offer an obvious technical bargain. The moving averages are bearish, with SMA_200 > SMA_20 > SMA_5, which indicates the broader trend remains down. Current pre-market price is 9.15, just below R1 at 9.331 and above pivot 8.668, so the stock is trapped in a tight range with resistance overhead. The pattern-based outlook is also weak, with a projected -8.11% next week and -9.41% next month.
Analysts recently raised price targets meaningfully: BofA to $27 from $24 and Clear Street to $28 from $21, both keeping Buy ratings. Both reports were driven by encouraging SOL-1 trial data, which they believe strengthens approval odds and supports Axpaxli in wet AMD and diabetic retinopathy-related opportunities. Hedge funds have also been aggressively buying, with reported buying up 2312.47% over the last quarter.
The stock’s one-year performance of +12.7% lags far behind the S&P 500 and Nasdaq. There is no recent congress trading data and no notable politician buying/selling reported.
Latest quarter season: Q1. OCUL reported $10.8 million in revenue and an $88.6 million loss, which shows strong top-line weakness relative to the scale of operating losses. That said, the company is still in a development/commercialization phase, so financial results are being driven more by clinical and regulatory progress than by stable earnings growth.
Analyst sentiment is bullish and improving. Recent updates from BofA and Clear Street both raised price targets sharply to $27 and $28, respectively, while maintaining Buy ratings. The Wall Street pros view is constructive on the company’s trial data and approval potential, but the bear case remains that the company is still unprofitable, faces regulatory uncertainty, and the stock price has not yet confirmed a strong upward trend.
